Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
90Y-ibritumomab tiuxetan + rituximab + melphalan + autologous stem cell transplant
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies, Beta-minus Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen, evaluated by the Mayo Clinic in a Phase 1 trial (NCT00477815), is designed as a conditioning treatment for patients with previously treated multiple myeloma undergoing autologous stem cell transplantation (ASCT). The regimen integrates radioimmunotherapy with standard high-dose chemotherapy. It consists of 90Y-ibritumomab tiuxetan (Zevalin), a murine monoclonal antibody targeting CD20 conjugated to the beta-emitting radioisotope yttrium-90, and rituximab, a chimeric anti-CD20 antibody. These are followed by high-dose melphalan, a bifunctional alkylating agent that causes DNA cross-linking. The goal of adding 90Y-ibritumomab tiuxetan to the melphalan conditioning is to deliver targeted radiation to malignant cells, potentially improving the depth of response before the infusion of autologous peripheral blood stem cells to restore hematopoiesis.
- Other names
- Zevalin + Melphalan + ASCT90Y-Zevalin + Rituximab + Melphalan + ASCTMayo Clinic multiple myeloma stem cell regimen
02
Targets
Beyond the preview
Go deeper on 90Y-ibritumomab tiuxetan + rituximab + melphalan + autologous stem cell transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 90Y-ibritumomab tiuxetan + rituximab + melphalan + autologous stem cell transplant.